The biotech company Orum has successfully secured $100 million in funding to advance its innovative approach that combines antibody-drug conjugates (ADCs) with protein degraders. This significant financial backing comes on the heels of a strategic pivot for the company, which has opted to discontinue its original lead program in favor of developing a new treatment aimed at blood cancers.
This shift underscores the growing interest and investment in novel therapeutic modalities that target cancer more effectively. By integrating ADCs with protein degradation technology, Orum aims to enhance the precision and efficacy of its treatment, potentially leading to improved outcomes for patients with hematological malignancies. The implications of this funding round extend beyond Orum, as it highlights a broader trend within the biotech industry towards innovative strategies that leverage existing technologies to address unmet medical needs.
Get started today with Solo access →
